Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-01-09 M&A Activity
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AstraZeneca acquire CinCor for cardiorenal asset
M&A Activity Classification · 1% confidence The document is an official announcement dated January 9, 2023, detailing AstraZeneca's definitive agreement to acquire CinCor Pharma. The content focuses on the strategic rationale, financial considerations ($1.3bn upfront cash offer, contingent value right), and the regulatory process (mentioning Schedule TO, Schedule 14D-9, and SEC filings like 10-K and 10-Q). This type of announcement, concerning a major corporate transaction (merger/acquisition), strongly aligns with the M&A Activity category. It is not a full financial report (10-K or IR), nor is it a general earnings release (ER). It is specifically about a takeover/merger proposal.
2023-01-09 English
SC TO-C Filing
Regulatory Filings
2023-01-09 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2023-01-03 English
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is a notification released via RNS (London Stock Exchange news service) dated January 3, 2023. The content explicitly states the total number of issued shares with voting rights (1,549,800,030) as of December 31, 2022, referencing the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of filing, which reports on the total voting rights and capital structure for regulatory compliance, fits best under the category related to general regulatory announcements or specific capital/share structure updates. Since it is a formal notification about the total number of voting rights, it is closely related to share capital structure. However, the primary mechanism of release is RNS, and the content is a standard regulatory disclosure about voting rights denominator, which often falls under general regulatory announcements if a more specific code isn't available. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most specific fit for a notification detailing the total voting rights denominator, although 'RNS' is the distribution channel. Since the core subject is the total number of voting rights, DVA is the most accurate classification for the content type, even though it is distributed via RNS.
2023-01-03 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2022-12-30 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an official notification disseminated via RNS (London Stock Exchange news service). The content explicitly details a 'Transaction by Person Discharging Managerial Responsibilities' (Pascal Soriot, CEO) involving the 'gift of shares to family members for nil consideration'. This directly corresponds to the definition of Director's Dealing (insider trades by executives). The filing code for this specific type of insider transaction report is DIRS.
2022-12-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.